The increase in CML cell adhesivity to FN was suppressed at higher dasatinib doses (e.g. 100 nM) corresponding to concentrations which are achieved in clinical settings [36]. The gene discussed is FN1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.